Üner, BurcuÖzdemir, SametTaş, ÇetinÜner, MelikeÖzsoy, Yıldız2023-04-032023-04-032023Üner, B., Özdemir, S., Taş, Ç., Üner, M., & Özsoy, Y. (2023). Loteprednol loaded nanoformulations for corneal delivery by quality by design concepts: Optimization, characterization, and anti infammatory activity. AAPS PharmSciTech, 24(4), pp. 1-15. https://doi.org/10.1208/s12249-023-02551-61530-9932https://doi.org/10.1208/s12249-023-02551-6https://hdl.handle.net/20.500.13055/435Loteprednol etabonate (LE) is a topical corticosteroid that uses inflammatory conditions of the eye. It has a low ocular bioavailability and side effects such as corneal disorder, eye discharge, and ocular discomfort. Therefore, it was decided to select the delivery systems, which are solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC), and nanoemulsion (NE). Design of experiments (DoE) of SLN, NLC, and NE formulations were formulated by using the quality by design (QbD) approach. Precirol® ATO 5 and oleic acid were used as solid and liquid lipids, respectively, in SLN, NLC, and NE formulations. Physiochemical characterization was performed on the formulations. The optimized formulations' inflammatory effects have been appraised on human corneal epithelial cells employing the ELISA test. Physicochemical characterization studies and inflammatory effects were appraised. The sizes of optimized formulations of SLN, NLC, and NE were 86.19 nm, 82.38 nm, and 126.35 nm, respectively, with minimum polydispersity. The release behavior of the formulations is composed of both diffusion and erosion. ELISA test results proved that the formulations significantly reduced IL-1 and IL-6 levels (p < 0.05). D-optimal mixture experimental design allowed us to develop the most precise formulations of SLN, NLC, and NE. Furthermore, the optimized formulations could be promising candidates for treating an inflammation-based corneal disease of the eye.eninfo:eu-repo/semantics/closedAccessDesign of ExperimentsLoteprednol EtabonateNanoemulsionNanostructured Lipid CarriersOphthalmic DeliveryQuality By DesignSolid Lipid NanoparticlesTopical CorticosteroidsArticle10.1208/s12249-023-02551-6244115Q22-s2.0-85151113476PMID: 36977841Q1